Zentalis Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-12-01
- Employees
- 168
- Market Cap
- $216.8M
- Website
- http://www.zentalis.com
- Introduction
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
Zentalis Pharmaceuticals Restructures to Advance Azenosertib in Gynecological Cancers
Zentalis Pharmaceuticals is restructuring to prioritize the late-stage development of azenosertib, a WEE1 inhibitor, for gynecological malignancies.
Azenosertib Shows Promise in Cyclin E1+ Platinum-Resistant Ovarian Cancer
Zentalis Pharmaceuticals presented updated clinical data on azenosertib, highlighting its potential in treating Cyclin E1+ platinum-resistant ovarian cancer (PROC).
FDA Lifts Clinical Hold on Zentalis' Azenosertib Trials, Boosting Cancer Research
The FDA has lifted the partial clinical hold on Zentalis Pharmaceuticals' azenosertib studies, allowing for the resumption of patient enrollment in ongoing trials.
FDA Lifts Partial Clinical Hold on Azenosertib Trials in Advanced Solid Tumors
The FDA has lifted the partial clinical hold on trials evaluating azenosertib, a WEE1 inhibitor, in patients with advanced solid tumors, allowing studies to resume enrollment.
FDA Lifts Partial Clinical Hold on Zentalis' Azenosertib Studies
The FDA has lifted the partial clinical hold on Zentalis Pharmaceuticals' azenosertib studies, allowing the company to resume enrollment in ongoing clinical trials.